Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)
Go back to Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)| (NASDAQ: IONS) | Delayed: 44.90 +0.46 (1.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.44 | 52 Week High | $62.68 | |||
| Open | $44.94 | 52 Week Low | $19.59 | |||
| Day High | $45.25 | P/E | N/A | |||
| Day Low | $44.20 | EPS | $0.00 | |||
| Volume | 4,521,357 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 27.74 +0.08 (0.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.66 | 52 Week High | $37.39 | |||
| Open | $27.65 | 52 Week Low | $28.25 | |||
| Day High | $27.92 | P/E | 16.81 | |||
| Day Low | $27.53 | EPS | $1.65 | |||
| Volume | 28,773,170 | |||||
